Mylan, NCPA herald GPhA generic savings report
PITTSBURGH — A report commissioned by the Generic Pharmaceutical Association has drawn applause from manufacturers and a retail pharmacy industry group.
Generic drug maker Mylan, a member of the GPhA, praised the report, conducted by market research firm IMS Health, showing that the use of generic prescription drugs saved consumers, patients and healthcare providers more than $931 billion over the last decade.
"Expanded use of generic drugs is one of the most effective ways to reduce healthcare costs," Mylan president Heather Bresch said. "It’s also one of the only universally agreed upon solutions to concerns related to healthcare expenditures. With 1-in-every-11 prescriptions dispensed in the [United States] being a Mylan product, we are proud to do our part in helping to reduce costs for consumers, payers and the U.S. healthcare system."
The National Community Pharmacists Association heralded the report as well. “Increasing the appropriate use of generic drugs is the fastest, most effective way to reduce prescription drug costs, and independent community pharmacists are helping to lead the way," NCPA EVP and CEO B. Douglas Hoey said. "The 2011 NCPA Digest, which is a snapshot of the
community pharmacy industry in 2010, indicates that local pharmacists dispensed generic drugs more often than ever — 72% of the time, up from 69% in 2009."
American Medical ID broadens reach with added distribution
HOUSTON — American Medical ID has expanded its reach by offering its medical identification bracelets and necklaces at three major drug stores.
The company said that beginning this month, its products now are available at 5,800 CVS locations, 7,200 Walgreens locations and 4,800 Rite Aid locations.
“It is wonderful to be working with these leading retail pharmacies who have a strong commitment to helping their customers stay healthy. They understand the importance and need for medical IDs and strive to make these life saving tools more accessible for their customers,” American Medical ID president and CEO Rick Russell said.
U.S. District Court blocks Mylan’s generic antibiotic
DUBLIN — A federal court in New Jersey has blocked an attempt by Mylan to market a generic version of a drug made by Warner Chilcott.
Warner Chilcott announced Thursday that the U.S. District Court for the District of New Jersey granted its motion for a preliminary injunction against Mylan to prevent it from launching a generic version of the antibiotic Doryx (doxycycline) in the 150-mg strength until the court makes a decision relating to a patent covering the drug, which Warner Chilcott and Mayne Pharmaceuticals allege Mylan to have infringed.
According to IMS Health, Doryx in the 150-mg strength represents more than 95% of Warner Chilcott’s entire Doryx franchise based on total prescriptions.